Loading…
Loading…
MIRM does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage, for any covered stock.
TapClick below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
TapClick below to see what's inside, then upgrade to unlock for MIRM and 80,000+ other tickers.
See price against where its own fundamentals say it should trade. The shaded gap is the discount or premium, across five valuation lenses.
TapClick below to see what's inside, then upgrade to unlock for MIRM and 80,000+ other tickers.
See exactly how MIRM's revenue becomes profit: a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for MIRM and 80,000+ other tickers.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia. Furthermore, the company is advancing Volixibat to address intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Founded in 2018, Mirum Pharmaceuticals, Inc. operates from its headquarters in Foster City, California.
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the fifteen ratings firms that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a sell rating, thirteen have assigned a buy rating and one has issued a strong buy rating on
Mirum Pharmaceuticals (NASDAQ: MIRM - Get Free Report) and Kiniksa Pharmaceuticals International (NASDAQ: KNSA - Get Free Report) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation. Analyst Recommendations This is a summary
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
MIRM's Livmarli meets the phase III EXPAND study goal, improving cholestatic pruritus and reducing serum bile acids, with an FDA filing planned for 2027.
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript